Juvenile Systemic Lupus Erythematosus and cholecystitis: Case reports and review of literature

Francisco Rivas-Larrauri, MD,* Noemi Gómez-Hernández, MD,** Marco Antonio Yamazaki-Nakashimada, MD,*** Rodolfo Rodríguez-Jurado, MD,**** Víctor Manuel Hernández-Bautista, MD,***** J Ramírez-Mayans, MD,****** Ana Luisa Rodríguez-Lozano, MD*******

* Pediatric Immunologist, Immunology Service Staff.
** Immunology Fellow.
*** Pediatric Immunologist, Immunology Service Staff.
**** Pathologist, Pathology Service Staff.
***** Pediatric Immunologist, Immunology Chief Service.
****** Pediatric Gastroenterologist, Gastroenterology Staff.
******* Corresponding author. Instituto Nacional de Pediatría, México, D.F.

Este artículo también puede ser consultado en versión completa en http://www.medigraphic.com/alergia

ABSTRACT

Juvenile Systemic Lupus Erythematosus (JSLE) is an autoimmune, multi-systemic disease with a wide range of clinical manifestations; however, the gallbladder disease is not well documented in the pediatric patients, there are few cases of cholecystitis in patients with JSLE in the world literature. We present three JSLE patients from the Immunology Service of the Instituto Nacional de Pediatría who developed cholecystitis during their evolution. We emphasize the awareness of this complication in these patients.

Key words: Juvenile Systemic Lupus Erythematosus, cholecystitis, abdominal pain.

INTRODUCTION

Systemic Lupus Erythematosus (SLE) is an autoimmune, multi-systemic disease with an unpredictable course and a wide range of clinical manifestations.1 It is known that the incidence of abdominal manifestations in adults is from 8 to 40% and acute cholecystitis represents 15% of them.2 There are few reports of gastrointestinal manifestations in children, Richer and cols., evaluated the frequency of gastrointestinal manifestations in French chil-
dren with SLE (JSLE) and found an incidence of 19%, reporting only one case of cholecystitis in 201 evaluated patients. Vesicular pathology is an unusual complication in patients with SLE, even though there are diverse risk factors for developing it in this disease.

We present three JSLE patients from the Immunology Service of the Instituto Nacional de Pediatría who developed cholecystitis during their evolution.

CASE PRESENTATION

CASE 1

A ten year-old female became ill 8 months prior to her hospitalization with malar rash, arthralgia, photosensitivity and muscular weakness. Diagnostic approach was initiated and met criteria for SLE (photosensitivity, discoid lupus, oral ulcers, proteinuria 5.4 g, ANA diffuse pattern 1:320, positive anti-DNAn, anti-SM > 100 U). She had hypocomplementemia C3 29.6 mg/dL, C4 < 6.18 mg/dL and dyslipidemia, 1,964 mg/dL triglycerides, 418 mg/dL cholesterol, negative serology for Antiphospholipid Antibody Syndrome (APS), which was treated with pulse methylprednisolone. During her hospitalization, she had acute abdominal pain associated to the ingestion of cholecystokinetic food, which was accompanied by nausea and biliary vomiting. Initial evaluation was normal, but because of persistence of pain in the right hypochondrium, an abdominal US was performed, showing thickening of the vesicular wall with biliary sludge, she had a conservative treatment and because of lupus was initiated with methylprednisolone and cyclophosphamide pulses, with good lupus evolution and remission of the abdominal symptoms. The patient continues to receive cyclophosphamide pulses due to neurolupus and nephritis. He has not had cholecystitis episodes and maintains a normal lipid profile.

CASE 2

A thirteen year-old male was initiated with asthenia, weight and hair loss, facial erythema, photosensitivity and intense generalized cephalia accompanied by nausea and conduct disorders. The patient met SLE criteria (malar erythema, oral ulcers, photosensitivity, arthritis, ANA 1:160, positive anti-DNAn, lymphopenia, hemolytic anemia, and 0.9 g proteinuria) and also had hypocomplementemia and hypergammaglobulinemia (IgG 2,009 mg/dL). The patient needed methylprednisolone pulses because of the activity and also received prednisone, azathioprine and hydroxychloroquine, and showed satisfactory progress. Three years later, he presented to the emergency room for abdominal pain in the right hypochondrium. Initial laboratory showed: triglycerides 465 mg/dL, cholesterol 214 mg/dL, HDL 22.3 mg/dL, LDL 144 mg/dL, VLDL 47.2 mg/dL. During inpatient evolution proteinuria, hematuria, hypocomplementemia and positive anti-DNAn were observed. An infectious process was made to initiate methylprednisolone pulses as a result of the activity data, with notable improvement of lupus activity and the cholecystitis, with no need for surgery. The patient continues to receive cyclophosphamide pulses due to neurolupus and nephritis. He has not had cholecystitis episodes and maintains a normal lipid profile.

CASE 3

A fourteen year-old female began ill with arthritis, 5 kg weight loss and purpuric lesions in the lower extremities. Pleural effusion was detected and the patient was diagnosed with SLE (lymphopenia, hemolytic anemia, pleural effusion, oral ulcers, ANA 1:320 and proteinuria). She was treated initially with azathioprine, cyclophosphamide and methylprednisolone pulses. However, since the proteinuria persisted, the decision was made to change to mycophenolate mofetil 60 mg/kg/d. Two years later a thyroid dysfunction was detected, triglycerides 859 mg/dL, cholesterol 434 mg/dL, HDL 40.3 mg/dL, LDL 241 mg/dL, VLDL 171 mg/dL and positive Anti B2 glycoprotein were documented for which treatment with levothyroxine and levastatin was initiated. After 6 months the patient entered with 2 days of abdominal pain in the epigastric region accompanied by alimentary vomiting, and positive Murphy’s sign. Normal pancreatic enzymes were reported and her cholesterol was 387 mg/dL, triglycerides 358 mg/dL. The abdominal US showed a cholelith in the gallbladder. She had lymphopenia and proteinuria of 4.6 g during her stay, for which it was decided to administer methylprednisolone pulses, and she showed improvement of the activity of the illness and cholecystitis symptoms. She is currently receiving 65 mg/kg/d of mycophenolate mofetil, is asymptomatic and on a cholecystokininetic-free diet.

DISCUSSION

The ubiquitous gastrointestinal manifestations in patients with SLE consist of oral ulcers, abdominal pain, gastrointestinal reflux, peritonitis, pancreatitis and hepatitis.
Among less frequent manifestations are dysphagia and cholecystitis.\(^\text{4,5}\)

Abdominal pain is a diagnostic and therapeutic challenge in these patients because it could have an autoimmune source secondary to concomitant illnesses, the side effects of the immunosuppressive treatment,\(^\text{4,5}\) and less common due to serositis.\(^\text{15}\)

Patients with SLE are prone to the formation of biliary sludge and lithiasis because of the presence of biliary dyskinesia caused by ischemia of the gallbladder.\(^\text{7}\) Reshetnyak et al., also found in patients with SLE the relationship between the use of corticosteroids and a metabolic lipid disorder, which predisposes the formation of biliary calculi.\(^\text{8}\)

Acute acalculous cholecystitis (AAC), which is non-distinguishable from lithiasic cholecystitis, is present in 5-10% of the patients with acute cholecystitis. It has been reported in patients with burns, severe trauma, infectious processes, prolonged parenteral nutrition, diabetes mellitus, APS and vasculitis. In vasculitis, patients with poliarteritis nodosa are at greater risk of presenting CAA. Echographic criteria proposed for diagnosing CAA include thickening of the gallbladder wall, edema around gallbladder and the absence of liths.\(^\text{9-10}\)

There are two main causes for gallbladder ischemia in SLE: vasculitis and thrombosis. Gallbladder vasculitis is characterized by the presence of acute periarterial fibrotic arteritis.\(^\text{9,10}\) Chen et al., separate gallbladder vasculitis into 3 groups: 1) vasculitis with manifestations of poliarteritis nodosa, 2) vasculitis occurring in aliment associated to vasculitis, such as systemic lupus erythematosus and 3) idiopathic vasculitis.\(^\text{11}\)

Thrombosis is more characteristic of SLE patients and is presented more frequently in patients with antiphospholipid antibodies. Histologically, multiple thrombi are appreciated in the veins of the gallbladder with no evidence of vasculitis.\(^\text{9-11}\)

Oclusive venous mesenteric inflammatory illness (OVII) is an infrequent cause of ACC in SLE with unknown etiology. Lie et al., reported that OVII belonged to a new category of vasculitis, in which inflammation is limited and affects intestinal veins and venules, specifically the mesenteric vein and its branches. Histologically, lymphocytic inflammatory with a necrotizing, granulomatous or mixed infiltrates and thrombosis are observed.\(^\text{12,19}\)

In 2006, we reported the case of a 17 year-old patient with SLE who reentered one year later for intense cramping abdominal pain, hemolytic anemia, proteinuria and lymphopenia. Elevated hepatic and pancreatic enzymes were also reported. The abdominal US (ultrasound) showed microlithiasis cholecystitis and pancreatitis. An open cholecystectomy was performed and the histopathology reports showed segmental necrotizing vasculitis. Treatment was started with pulse methylprednisolone and cyclophosphamide and the patient showed improvement. Because of the histopathological findings and data regarding clinical activity, it was considered that the cholecystitis was part of the damage caused by the disease’s activity.\(^\text{14}\)

In 1983, Swanepoel\(^\text{17}\) was the first to describe the association between CAA and SLE, since then different reports have been issued.\(^\text{18-22}\) In Table I summarizes the main alterations our patients share with cases reported previously. It attracts our attention that the 3 cases reported here and the one reported previously\(^\text{14}\) by our Institute have lupus nephritis and hypertriglyceridemia, in comparison to only two of the rest of the reports. On the other hand, the presence of hemolytic anemia in two of the patients associated to other activity data on the disease, as could be the increase in proteinuria, leads to conclude that: 1. Patients with juvenile SLE go through a more aggressive illness, with greater multi-organ affliction. 2. In patients with disease activity that present abdominal pain, cholecystitis should be suspected. As mentioned by Mendoca et al., it is possible that acalculous cholecystitis is under diagnosed since the abdominal ultrasound is not part of the routine examination for patients with SLE. It is also important to comment that it is possible that data on vasculitis could not appear in the histopathological report of the first case because the patient received immunosuppressant treatment and was surgically intervened during a sub-acute stage.

CONCLUSIONS

Cholecystitis causes unsuspected and rather unrecognized abdominal pain in SLE patients. In the Institute’s Lupus Clinic, we treat 119 patients, and only 4 of them have shown this entity. It attracts attention that in patients we reported and in 1 of the pediatric patients reported in the literature (Table I), developed cholecystitis and lupus nephritis, for which more studies should be done to conclude that a direct relationship does exist.

Despite the multiple risks factors known in the SLE patients to develop cholecystitis, the fact is this entity is very uncommon in JSLE patients in large series, this is why it is a remarkable finding that three patients presented with activity of their illness, hypertrigliceridemia and hypercholesterolemia developed cholecystitis, more studies are need to determine if the activity illness and/or dyslipidemia could be the trigger, and permit identify this patients as high risk of complications.

To our knowledge this is the first cases reported in Mexican children with JSLE and cholecystitis.

We believe that acute cholecystitis, especially acalculous, should be suspected in SLE patients with abdominal pain, particularly those showing activity of the illness, and an abdominal US should be ordered as soon as possible.
Table I. Summary of SLE patients with cholecystitis.

<table>
<thead>
<tr>
<th>Author</th>
<th>Gender</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Morbidity</th>
<th>Histopathology</th>
<th>Serology +</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>F</td>
<td>10</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>De Leon et al.</td>
<td>F</td>
<td>17</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>Anti-Sm</td>
</tr>
<tr>
<td>Swanepeol et al.</td>
<td>F</td>
<td>22</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Newbold et al.</td>
<td>F</td>
<td>28</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Newbold et al.</td>
<td>F</td>
<td>38</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Kamikura et al.</td>
<td>F</td>
<td>27</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Rhoton et al.</td>
<td>F</td>
<td>22</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Nolen et al.</td>
<td>F</td>
<td>22</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Desailloud et al.</td>
<td>F</td>
<td>29</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Shin et al.</td>
<td>F</td>
<td>39</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Bando et al.</td>
<td>F</td>
<td>43</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Kara et al.</td>
<td>M</td>
<td>65</td>
<td>APS</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Baristaina et al.</td>
<td>M</td>
<td>10</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
<tr>
<td>Mendoça et al.</td>
<td>F</td>
<td>12</td>
<td>SLE</td>
<td>Lupus nephritis</td>
<td>AAC Hypertriglyceridemia</td>
<td>ANA</td>
</tr>
</tbody>
</table>


BIBLIOGRAPHY


Corresponding author:
Ana Luisa Rodríguez Lozano, MD
Pediatric Rheumatologist, Medical Researcher
Immunology Service. Instituto Nacional de Pediatría
Insurgentes Sur 3700-C, Col. Insurgentes Cuicuilco 04530 México City, México
Tel/Fax +52 55 1084 0900 ext 1337
E-mail: anarheum@yahoo.com.mx